Literature DB >> 8509359

The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat.

G R Screaton1, M V Bell, J I Bell, D G Jackson.   

Abstract

The human CD44 cell surface glycoprotein family which has been implicated in lymphocyte homing, tumor metastasis, and extracellular matrix attachment consists of a large number of related isoforms that derive from the differential splicing of a single CD44 gene transcript. Recent mapping of the CD44 locus in man indicated the presence of at least nine alternative exons within the region of the gene encoding the variable membrane proximal extracellular domain. Here we report the identification of a 10th alternative exon (termed V1) in the mouse, human, and rat CD44 genes. We demonstrate tissue-specific patterns of expression for transcripts containing exons V1-V10 in the mouse and a highly restricted usage of exon V1 in transcripts from mouse gastric tissue. Close sequence homology between exons V1-V10 from mouse rat and human points to a specific functional role rather than a purely structural role for the membrane proximal extracellular domain of the CD44 molecule.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8509359

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell.

Authors:  Toshifumi Yae; Kenji Tsuchihashi; Takatsugu Ishimoto; Takeshi Motohara; Momoko Yoshikawa; Go J Yoshida; Takeyuki Wada; Takashi Masuko; Kaoru Mogushi; Hiroshi Tanaka; Tsuyoshi Osawa; Yasuharu Kanki; Takashi Minami; Hiroyuki Aburatani; Mitsuyo Ohmura; Akiko Kubo; Makoto Suematsu; Kazuhisa Takahashi; Hideyuki Saya; Osamu Nagano
Journal:  Nat Commun       Date:  2012-06-06       Impact factor: 14.919

2.  Embryonic neurons of the developing optic chiasm express L1 and CD44, cell surface molecules with opposing effects on retinal axon growth.

Authors:  D W Sretavan; L Feng; E Puré; L F Reichardt
Journal:  Neuron       Date:  1994-05       Impact factor: 17.173

3.  CD44 isoform expression follows two alternative splicing pathways in breast tissue.

Authors:  X Roca; J L Mate; A Ariza; A M Muñoz-Mármol; C von Uexküll-Güldeband; I Pellicer; J J Navas-Palacios; M Isamat
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

4.  Influence of intron length on alternative splicing of CD44.

Authors:  M V Bell; A E Cowper; M P Lefranc; J I Bell; G R Screaton
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

Review 5.  CD44 and the adhesion of neoplastic cells.

Authors:  Z Rudzki; S Jothy
Journal:  Mol Pathol       Date:  1997-04

Review 6.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

Authors:  J T Isaacs
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

7.  CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.

Authors:  M Kryworuckho; F Diaz-Mitoma; A Kumar
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 8.  Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression.

Authors:  Lilly Y W Bourguignon
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

Review 9.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

10.  Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.

Authors:  Lilly Y W Bourguignon; Weiliang Xia; Gabriel Wong
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.